Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090090
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2004-08-24
Brief Title:
Elsamitrucin SPI 28090 for Relapsed or Refractory Non-Hodgkins Lymphoma
Sponsor:
Spectrum Pharmaceuticals Inc
Organization:
Spectrum Pharmaceuticals Inc
Organization Data
Organization:
Spectrum Pharmaceuticals Inc
Class:
INDUSTRY
Study ID:
ELSA 2004-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Spectrum Pharmaceuticals Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None